Protein/peptide injection delivery, also known as protein/peptide parenteral delivery, is currently the most commonly used method for clinical administration of therapeutic proteins/peptides. As an expert in the development of protein/peptide delivery systems, CD Formulation is committed to assisting our global customers in developing powerful protein/peptide injectable delivery products. Our team of experienced researchers and scientists work closely with our clients to design customized delivery systems that ensure optimal efficacy and safety of protein/peptide therapies.
Most protein and peptide drugs on the market are administered parenterally, such as subcutaneous (sc), intramuscular, or intravenous (iv) injection. Compared with oral and pulmonary administration, the potential advantages of parenteral administration include:
However, parenteral protein and peptide administration also has several limitations, including:
Fig. 1 Colloidal carriers for protein and peptide parenteral delivery. (Patel A, et al., 2014)
CD Formulation is an expert in therapeutic protein/peptide science and formulation science, focusing on combining advanced formulation technology with protein/peptide knowledge to develop first-class protein/peptide injectable delivery systems.
Our scientists deploy a range of strategies, such as nanotechnology, the addition of stabilizing excipients, surface modification, lyophilization technology, and micronization technology to improve the bioavailability and stability of these challenging molecules.
Thanks to decades of experience in protein/peptide delivery system development, we have successfully established a professional injectable platform, focusing on the development and commercialization of various injectable formulations. Our injectable platform is equipped with first-class equipment and cutting-edge nanotechnology to overcome any problems that proteins/peptides may have, such as easy aggregation and degradation, instability, and low bioavailability.
Our protein/peptide injectable delivery system capabilities include:
Fig. 2 Proteins/peptides injectable delivery system. (CD Formulation)
Technologies | Description |
Liposome Technology | Protein/peptide drugs are encapsulated in liposomes to improve drug solubility, stability, and bioavailability. |
Nanoemulsion Technology | Protein/peptide drugs with poor water solubility are encapsulated in the oil phase to improve bioavailability. |
Microemulsion Technology | Protein/peptide drugs are encapsulated in a protective shell to improve the stability and bioavailability of injectable suspensions. |
Polymer Nanoparticle Technology | Protein/peptide drugs are encapsulated in polymer mechanisms to enhance drug stability and deliver therapeutic agents to specific target sites in the body. |
Micronization Technology | Protein/peptide solutions are converted into injectable powders/particles under suitable conditions by freeze-drying or spray-freeze drying technology. |
Published Data
Technology: Nanoparticles Technology
Journal: Int J Nanomedicine
IF: 7.033
Published: 2013
Results:
The authors synthesized polyethylene glycol (PEG) and polylactic acid (PLA) based copolymer nanoparticles and investigated their role as vehicles for prolonged insulin delivery via parenteral route. Insulin loading was achieved using double emulsion solvent evaporation technique. The synthesized copolymers and nanoparticles were analyzed by standard polymer characterization techniques such as gel permeation chromatography, dynamic light scattering, nuclear magnetic resonance, and transmission electron microscopy and in vitro insulin release studies were performed under simulated conditions. The effect of parenteral delivery was evaluated by subcutaneous injection of nanoparticles with different insulin loads into a diabetic rabbit model. The results showed that a single subcutaneous injection of PLA-PEG 4000 nanoparticles containing 50 IU insulin load/kg body weight was effective in maintaining blood glucose levels above the physiological normal range of 90-140 mg/dL for more than 7 days. This suggests that polyethylene glycol (PEG) and polylactic acid (PLA) based copolymer nanoparticles have the potential for parenteral delivery of insulin.
Fig. 3 Molecular mass distribution of PLA-PEG copolymer determined by gel permeation chromatography. (Tomar L, et al., 2013)
CD Formulation is always at the forefront of protein/peptide injectablel delivery system development, mastering the most cutting-edge technologies and methods. Please don't hesitate to contact us if you are interested in our services.
References